Partnering and Pipeline

We provide a wide range of R&D opportunities.

Partnering & Pipeline

By 2030, the number of AD and DLB patients are increasing to 4 and 0.5 millions, respectively, in Japan. However, disease-modifying therapeutics remains undeveloped. We supply technologies to define prodromal dementia and support the patients using brain rehabilitation technologies for longevity with healthy brain.

Alliance Partners

  • Development of diagnosis technologies for the healthy aging in brain(AMED, Sendai Nishitaga Hospital)

  • Development for therapeutics for prodromal dementia(Tohoku University, Tottori University, Shiratori Pharmaceutical company)

  • Supporting healthy brain aging by supplements and foods(Food companies)

  • Monitoring of brain inflammation to prevent brain attack(Kurume University)

  • Supporting autism spectrum disorders by brain monitoring and therapy(Fukui Medical University, SBI Pharma)